Here's the actual paper: http://www.impactaging.com/papers/v6/n9/full/100690.html Abstract This r...
Here's the actual paper: http://www.impactaging.com/papers/v6/n9/full/100690.html Abstract This report describes a novel, comprehensive, and personalized therapeutic program that is based on the underlying pathogenesis of Alzheimer's disease, and which involves multiple modalities designed to achieve metabolic enhancement for neurodegeneration (MEND). The first 10 patients who have utilized this program include patients with memory loss associated with Alzheimer's disease (AD), amnestic mild cognitive impairment (aMCI), or subjective cognitive impairment (SCI). Nine of the 10 displayed subjective or objective improvement in cognition beginning within 3-6 months, with the one failure being a patient with very late stage AD. Six of the patients had had to discontinue working or were struggling with their jobs at the time of presentation, and all were able to return to work or continue working with improved performance. Improvements have been sustained, and at this time the longest patient follow-up is two and one-half years from initial treatment, with sustained and marked improvement. These results suggest that a larger, more extensive trial of this therapeutic program is warranted. The results also suggest that, at least early in the course, cognitive decline may be driven in large part by metabolic processes. Furthermore, given the failure of monotherapeutics in AD to date, the results raise the possibility that such a therapeutic system may be useful as a platform on which drugs that would fail as monotherapeutics may succeed as key components of a therapeutic system.
Posted by drewvolpe on Oct 2, 2014, 7:36 PM
Tags
Related issues
- I wish there was more actual research on those 'moralisms' many of which boil down to public health safety features that have led to dram...
- [Bug]: Downloads fail with "Got more than 8190 bytes when reading" due to GitHub's new 9KB+ CSP header on release redirects
- Investigate path resolution for "libflutter.so" binary
- Although I'm very hesitant to put too much faith into anything in the area of nutrition and health based on a single study, I do recall r...
- I don't know the demographics of your students but I'm always intrigued when I'm able to quickly get productive with what I'm currently l...
- > hopefully slow down the trend of the elites making massive amounts of money with financial transactions instead of BUILDING THINGS and ...
Raise real-world problems, find people facing the same issue, and discuss solutions.9,000 issues0 comments
reliability (Healthcare)
I wish there was more actual research on those 'moralisms' many of which boil down to public health safety features that have led to dram...
New[Bug]: Downloads fail with "Got more than 8190 bytes when reading" due to GitHub's new 9KB+ CSP header on release redirects
Investigate path resolution for "libflutter.so" binary
Although I'm very hesitant to put too much faith into anything in the area of nutrition and health based on a single study, I do recall r...
I don't know the demographics of your students but I'm always intrigued when I'm able to quickly get productive with what I'm currently l...
> hopefully slow down the trend of the elites making massive amounts of money with financial transactions instead of BUILDING THINGS and ...
If you want to be utilitarian about it, maximizing common good derived from a modest donation, then pick (a) the venture that will produc...
I really think we're dealing with some very complicated biochemistry here.
Here's the actual paper: http://www.impactaging.com/papers/v6/n9/full/100690.html Abstract This r...
Here's the actual paper: http://www.impactaging.com/papers/v6/n9/full/100690.html Abstract This report describes a novel, comprehensive, and personalized therapeutic program that is based on the underlying pathogenesis of Alzheimer's disease, and which involves multiple modalities designed to achieve metabolic enhancement for neurodegeneration (MEND). The first 10 patients who have utilized this program include patients with memory loss associated with Alzheimer's disease (AD), amnestic mild cognitive impairment (aMCI), or subjective cognitive impairment (SCI). Nine of the 10 displayed subjective or objective improvement in cognition beginning within 3-6 months, with the one failure being a patient with very late stage AD. Six of the patients had had to discontinue working or were struggling with their jobs at the time of presentation, and all were able to return to work or continue working with improved performance. Improvements have been sustained, and at this time the longest patient follow-up is two and one-half years from initial treatment, with sustained and marked improvement. These results suggest that a larger, more extensive trial of this therapeutic program is warranted. The results also suggest that, at least early in the course, cognitive decline may be driven in large part by metabolic processes. Furthermore, given the failure of monotherapeutics in AD to date, the results raise the possibility that such a therapeutic system may be useful as a platform on which drugs that would fail as monotherapeutics may succeed as key components of a therapeutic system.
Comments (0)
No comments yet. Start the discussion.